MENTICE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27 SEK | -1.82% |
|
-0.37% | -43.40% |
| May. 21 | Mentice AB Announces Göran Malmberg Will Leave Position as CEO | CI |
| May. 16 | Mentice Receives USD 2.26 Million Order for Simulation Solutions from a Top 20 Global MedTech Company | CI |
| Sales 2024 * | 288M 27.25M | Sales 2025 * | 353M 33.41M | Capitalization | 703M 66.52M |
|---|---|---|---|---|---|
| Net income 2024 * | -11M -1.04M | Net income 2025 * | 19M 1.8M | EV / Sales 2024 * | 2.24 x |
| Net cash position 2024 * | 56.64M 5.36M | Net cash position 2025 * | 77.51M 7.33M | EV / Sales 2025 * | 1.77 x |
| P/E ratio 2024 * |
-61.2
x | P/E ratio 2025 * |
35.7
x | Employees | 128 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mentice AB
More press releases
| 1 day | +0.73% | ||
| 1 week | +2.21% | ||
| Current month | +2.59% | ||
| 1 month | -9.18% | ||
| 3 months | -21.31% | ||
| 6 months | -27.68% | ||
| Current year | -41.93% |
1 week
26.90
28.80
1 month
26.5033.50
Current year
26.5071.40
1 year
25.1071.40
3 years
25.10185.00
5 years
25.10185.00
10 years
25.10185.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 98-12-31 | |
| Chief Executive Officer | 76 | 07-12-31 | |
Jonatan Sjostrom
COO | Chief Operating Officer | - | 23-09-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 07-12-31 | |
Magnus Nilsson
CHM | Chairman | 68 | 22-04-26 |
| Director/Board Member | 71 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 27 | -1.82% | 14 198 |
| 24-06-07 | 27.5 | +0.73% | 12,098 |
| 24-06-05 | 27.3 | +0.74% | 3,687 |
| 24-06-04 | 27.1 | 0.00% | 1,461 |
| 24-06-03 | 27.1 | +0.37% | 18,702 |
Delayed Quote Nasdaq Stockholm, June 10, 2024 at 06:26 am EDT
More quotes
Mentice AB is a Sweden-based medical technology company. It provides software and hardware simulation solutions and related services for endovascular therapies. The Companyâs solutions help healthcare professionals acquire, retain, and enhance their procedural skills. The Companyâs solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. The Company also covers neurovascular, cardiovascular and peripheral interventions, among others. It is active globally.
Calendar
2024-07-23
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
27.5
SEK
Average target price
45
SEK
Spread / Average Target
+63.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.93% | 66.71M | |
| -24.88% | 7.32B | |
| +7.04% | 6.66B | |
| +15.10% | 5.5B | |
| -17.74% | 4.88B | |
| +14.96% | 4.1B | |
| -20.83% | 3.89B | |
| -25.03% | 2.83B | |
| +44.01% | 2.31B | |
| +2.10% | 2.07B |
- Stock Market
- Equities
- MNTC Stock
